119 related articles for article (PubMed ID: 8107619)
1. Effects of salmon calcitonin suppositories in the prevention of bone loss in oophorectomized women.
Polatti F; Perotti F; Angelini GP; Vassellatti D; Rapisardi I
Maturitas; 1993 Dec; 18(1):73-6. PubMed ID: 8107619
[TBL] [Abstract][Full Text] [Related]
2. Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women.
Fioretti P; Gambacciani M; Taponeco F; Melis GB; Capelli N; Spinetti A
Maturitas; 1992 Dec; 15(3):225-32. PubMed ID: 1465036
[TBL] [Abstract][Full Text] [Related]
3. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
Reginster JY; Deroisy R; Lecart MP; Sarlet N; Zegels B; Jupsin I; de Longueville M; Franchimont P
Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
[TBL] [Abstract][Full Text] [Related]
5. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.
Kollerup G; Hermann AP; Brixen K; Lindblad BE; Mosekilde L; Sørensen OH
Calcif Tissue Int; 1994 Jan; 54(1):12-5. PubMed ID: 8118746
[TBL] [Abstract][Full Text] [Related]
6. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study.
Overgaard K
Calcif Tissue Int; 1994 Aug; 55(2):82-6. PubMed ID: 7953984
[TBL] [Abstract][Full Text] [Related]
7. [Prevention of post-ovariectomy osteoporosis in the rat. Comparative study of synthetic salmon calcitonin and eel calcitonin aminosuberic analogue].
Gnudi S; Zati A; Giardino R; Fini M; Pratelli L; Orlandi M; Figus E
Minerva Endocrinol; 1993 Sep; 18(3):123-7. PubMed ID: 8183179
[TBL] [Abstract][Full Text] [Related]
8. [Synthetic salmon calcitonin suppositories for the short-term treatment of involutive osteoporosis].
Isaia GC; Di Stefano M; Sciolla A; Mussetta M; Vassellatti D
Minerva Med; 1995 Mar; 86(3):101-4. PubMed ID: 7603605
[TBL] [Abstract][Full Text] [Related]
9. Prevention of postmenopausal bone loss by rectal calcitonin.
Reginster JY; Jupsin I; Deroisy R; Biquet I; Franchimont N; Franchimont P
Calcif Tissue Int; 1995 Jun; 56(6):539-42. PubMed ID: 7648483
[TBL] [Abstract][Full Text] [Related]
10. The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.
Tascioglu F; Colak O; Armagan O; Alatas O; Oner C
Rheumatol Int; 2005 Nov; 26(1):21-9. PubMed ID: 15688191
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
Tankó LB; Bagger YZ; Alexandersen P; Devogelaer JP; Reginster JY; Chick R; Olson M; Benmammar H; Mindeholm L; Azria M; Christiansen C
J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
[TBL] [Abstract][Full Text] [Related]
12. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
[TBL] [Abstract][Full Text] [Related]
13. Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause.
Melis GB; Cagnacci A; Bruni V; Falsetti L; Jasonni VM; Nappi C; Polatti F; Volpe A
Maturitas; 1996 May; 24(1-2):83-90. PubMed ID: 8794438
[TBL] [Abstract][Full Text] [Related]
14. An effective regimen of intranasal salmon calcitonin in early postmenopausal bone loss.
Gennari C; Agnusdei D; Montagnani M; Gonnelli S; Civitelli R
Calcif Tissue Int; 1992 Apr; 50(4):381-3. PubMed ID: 1571851
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
Chesnut CH; Silverman S; Andriano K; Genant H; Gimona A; Harris S; Kiel D; LeBoff M; Maricic M; Miller P; Moniz C; Peacock M; Richardson P; Watts N; Baylink D
Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
[TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
17. Prevention of osteoporosis with nasal salmon calcitonin: effect of anti-salmon calcitonin antibody formation.
Reginster JY; Gaspar S; Deroisy R; Zegels B; Franchimont P
Osteoporos Int; 1993 Sep; 3(5):261-4. PubMed ID: 8400608
[TBL] [Abstract][Full Text] [Related]
18. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
Wang SX; Li H
Chin Med J (Engl); 2008 Jul; 121(14):1280-4. PubMed ID: 18713548
[TBL] [Abstract][Full Text] [Related]
19. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
Perrone G; Galoppi P; Valente M; Capri O; D'Ubaldo C; Anelli G; Zichella L
Gynecol Obstet Invest; 1992; 33(3):168-71. PubMed ID: 1612530
[TBL] [Abstract][Full Text] [Related]
20. Effect of different doses of nasal salmon calcitonin on bone mass.
Thamsborg G; Storm TL; Sykulski R; Brinch E; Nielsen HK; Sørensen OH
Calcif Tissue Int; 1991 May; 48(5):302-7. PubMed ID: 2054714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
